Parkinson’s Disease – Pipeline Review, H2 2019

“Global Markets Direct’s, ‘Parkinson’s Disease – Pipeline Review, H2 2019’, provides an overview of the Parkinson’s Disease pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Parkinson’s Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Parkinson’s Disease and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.”

Scope


– The report provides a snapshot of the global therapeutic landscape of Parkinson’s Disease

– The report reviews pipeline therapeutics for Parkinson’s Disease by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Parkinson’s Disease therapeutics and enlists all their major and minor projects

– The report assesses Parkinson’s Disease therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Parkinson’s Disease”

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Parkinson's Disease

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Parkinson's Disease pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

“1st Bio Therapeutics Inc

4D Pharma Plc

Abaxy Sprl

AbbVie Inc

Abivax SA

ABL Bio Inc

AC Immune SA

Acelot Inc

AcuraStem Inc

Addex Therapeutics Ltd

Advanced Medical Projects

Afecta Pharmaceuticals Inc

Affichem SA

AFFiRiS AG

Alan Laboratories Inc

Alectos Therapeutics

Alexza Pharmaceuticals Inc

Alion Pharmaceuticals Inc

Alkahest Inc

Alkermes Plc

Allife Medical Science and Technology Co Ltd

Alterity Therapeutics Ltd

Amabiotics SAS

Amarantus Bioscience Holdings Inc

Amathus Therapeutics Inc

Amneal Pharmaceuticals Inc

Anavex Life Sciences Corp

Anida Pharma Inc

Annovis Bio Inc

Antoxis Ltd

Aoxing Pharmaceutical Company Inc

APeT Holding BV

Apollo Therapeutics LLC

Appello Pharmaceuticals Inc

AptaBio Therapeutics Inc

Aptamer Sciences Inc

Araclon Biotech SL

Aranda Pharma Ltd

AriBio

ArmaGen Inc

Arrien Pharmaceuticals LLC

Arvinas Inc

Asdera

Asklepios BioPharmaceutical Inc

AstraZeneca Plc

Athersys Inc

Athira Pharma Inc

AurimMed Pharma Inc

Auritec Pharmaceuticals Inc

Axial Biotherapeutics Inc

Axovant Gene Therapies Ltd

AZTherapies Inc

B&A Therapeutics

BCWorld Pharm Co Ltd

Belrose Pharma Inc

Berg LLC

Bial – Portela & Ca SA

Bio-Modeling Systems SAS

Bioasis Technologies Inc

BioElectron Technology Corp

Biogen Inc

BioHealthonomics Inc

BlueRock Therapeutics

BrainStorm Cell Therapeutics Inc

Bristol-Myers Squibb Co

C4X Discovery Holdings Plc

Calico LLC

Califia Bio Inc

Cantabio Pharmaceuticals Inc

Canvax Biotech SL

Capo Therapeutics Inc

Carmot Therapeutics Inc

Carna Biosciences Inc

Cavion LLC

CavoGene LifeSciences

CellCure

Cellivery Therapeutics Inc

Cellix Bio Pvt Ltd

Cerecin Inc

CereSpir Inc

Cerevance Inc

Cerevel Therapeutics LLC

CHA Bio & Diostech Co Ltd

Chase Therapeutics Corp

Chipscreen Biosciences Ltd

CholesteniX Ltd

Ci Therapeutics

Clayton Biotechnologies Inc

Clene Nanomedicine Inc

Clera Inc

Clevexel Pharma SAS

Cogentis Therapeutics Inc

Collaborative Medicinal Development LLC

Contera Pharma ApS

Copernicus Therapeutics Inc

Corium International Inc

Crossject SA

CuraSen Therapeutics Inc

Curemark LLC

CuroNZ Ltd

Curyx Bio Inc

Cypralis Ltd

DanPET AB

Declion Pharmaceuticals Inc

DegenRx BV

Denali Therapeutics Inc

DermaXon LLC

Diffusion Pharmaceuticals Inc

Dina Pharmaceuticals Inc

Dizlin Medical Design AB

Domain Therapeutics SA

DongKoo Bio & Pharma Co Ltd

E-scape Bio Inc

Easywell Biomedical Inc

Eisai Co Ltd

Eli Lilly and Co

Emerald Health Sciences Inc

Energenesis Biomedical Co Ltd

Evgen Pharma Plc

Fabre-Kramer Pharmaceuticals Inc

Fortuna Fix Inc

Fulcrum Therapeutics Inc

GB Sciences Inc

Genervon Biopharmaceuticals LLC

GenKyoTex SA

Genmab A/S

Genzyme Corp

Gismo Therapeutics Inc

GlaxoSmithKline Plc

Global BioLife Inc Ltd

GNT Pharma Co Ltd

Grespo AB

GT Gain Therapeutics SA

Guangzhou Magpie Pharmaceutical Co Ltd

Guangzhou-Sheng Jian Chi Pharmaceutical Co Ltd

H. Lundbeck AS

Hanmi Pharmaceuticals Co Ltd

Hebei Newtherapy BIo-Pharma Technology Co Ltd

Hemostemix Inc

Herantis Pharma Plc

HitGen LTD

Hong Kong WD Pharmaceutical Co Ltd

Hope Biosciences LLC

ICB International Inc

Icure Pharmaceutical Inc

ID Pharma Co Ltd

Imago Pharmaceuticals Inc

Immune Modulation Inc

Immungenetics AG

Impel NeuroPharma Inc

Inflazome Ltd

Inhibikase Therapeutics Inc

InnoMedica Holding AG

Intec Pharma Ltd

International Stem Cell Corp

Intra-Cellular Therapies Inc

Invisio Ltd

Io Therapeutics Inc

Ionis Pharmaceuticals Inc

IRLAB Therapeutics AB

Jazz Pharmaceuticals Plc

Jeil Pharmaceutical Co Ltd

Junaxo Inc

Kainos Medicine Inc

Kariya Pharmaceuticals IVS

Kashiv BioSciences LLC

Keapstone Therapeutics Ltd

Kissei Pharmaceutical Co Ltd

Kyowa Kirin Co Ltd

LA Cell Inc

Lauren Sciences LLC

Lead Discovery Center GmbH

Living Cell Technologies Ltd

Longevity Biotech Inc

Luye Pharma Group Ltd

Lysosomal Therapeutics Inc

M et P Pharma AG

Macrobian Biotech BV

Mavalon Therapeutics Ltd

Med-Life Discoveries LP

MedGenesis Therapeutix Inc

MeiraGTx Holdings Plc

Merck & Co Inc

Meta-IQ ApS

Metabolic Solutions Development Company LLC

MetVital Inc

MimeTech Srl

Minerva Neurosciences Inc

Mission Therapeutics Ltd

Mitochon Pharmaceuticals Inc

Mitoconix Bio Ltd

MitoDys Therapeutics Ltd

Mitokinin LLC

Mitsubishi Tanabe Pharma Corp

Modag GmbH

Montisera Ltd

Motac Neuroscience Ltd

Nanna Therapeutics Ltd

NeoCytex Biopharma Inc

Neonc Technologies Inc

Netherlands Translational Research Center BV

NeuBase Therapeutics Inc

NeuExcell Therapeutics Inc

Neuracle Science Co Ltd

Neuraly Inc

Neuren Pharmaceuticals Ltd

Neuro Vigor LLC

Neurocea Pharmaceuticals

Neurochlore

Neurodon LLC

Neurodyn Life Sciences Inc

Neuroene Therapeutics LLC

NeuroGeneration Inc

Neurona Therapeutics Inc

NeuroNascent Inc

NeuroPn Therapeutics LLC

Neuropore Therapies Inc

Neurotrope Bioscience Inc

New Amsterdam Sciences Inc

New Biotic Inc

New World Laboratories Inc

Newron Pharmaceuticals SpA

Nitrome Biosciences Inc

nLife Therapeutics SL

NLS Pharma Group

Novartis AG

Novo Nordisk AS

NTZ Lab Ltd

NutriBand Inc

Omeros Corp

Oncodesign SA

OPKO Health Inc

Orpheris Inc

Oryzon Genomics SA

Parkure Ltd

Peptron Inc

Pfizer Inc

Pharma Two B Ltd

PharmatrophiX Inc

Pharmicell Co Ltd

Pharnext SA

Phoenix Biotechnology Inc

Phoenix Life Sciences International Ltd

Pivot Pharmaceuticals Inc

PK Biosciences Corp

Plex Pharmaceuticals Inc

Polaryx Therapeutics Inc

PolyCore Therapeutics LLC

Prevail Therapeutics Inc

Priavoid GmbH

Primary Peptides Inc

Proclara Biosciences Inc

Table of Contents

Table of Contents

Table of Contents 2

Introduction 10

Parkinson's Disease - Overview 11

Parkinson's Disease - Therapeutics Development 12

Parkinson's Disease - Therapeutics Assessment 55

Parkinson's Disease - Companies Involved in Therapeutics Development 75

Parkinson's Disease - Drug Profiles 152

Parkinson's Disease - Dormant Projects 809

Parkinson's Disease - Discontinued Products 828

Parkinson's Disease - Product Development Milestones 830

Appendix 840

List of Tables

“List of Tables

Number of Products under Development for Parkinson’s Disease, H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products under Development by Universities/Institutes, H2 2019

Products under Development by Companies, H2 2019

Products under Development by Universities/Institutes, H2 2019

Number of Products by Stage and Target, H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Parkinson’s Disease – Pipeline by 1st Bio Therapeutics Inc, H2 2019

Parkinson’s Disease – Pipeline by 4D Pharma Plc, H2 2019

Parkinson’s Disease – Pipeline by Abaxy Sprl, H2 2019

Parkinson’s Disease – Pipeline by AbbVie Inc, H2 2019

Parkinson’s Disease – Pipeline by Abivax SA, H2 2019

Parkinson’s Disease – Pipeline by ABL Bio Inc, H2 2019

Parkinson’s Disease – Pipeline by AC Immune SA, H2 2019

Parkinson’s Disease – Pipeline by Acelot Inc, H2 2019

Parkinson’s Disease – Pipeline by AcuraStem Inc, H2 2019

Parkinson’s Disease – Pipeline by Addex Therapeutics Ltd, H2 2019

Parkinson’s Disease – Pipeline by Advanced Medical Projects, H2 2019

Parkinson’s Disease – Pipeline by Afecta Pharmaceuticals Inc, H2 2019

Parkinson’s Disease – Pipeline by Affichem SA, H2 2019

Parkinson’s Disease – Pipeline by AFFiRiS AG, H2 2019

Parkinson’s Disease – Pipeline by Alan Laboratories Inc, H2 2019

Parkinson’s Disease – Pipeline by Alectos Therapeutics, H2 2019

Parkinson’s Disease – Pipeline by Alexza Pharmaceuticals Inc, H2 2019

Parkinson’s Disease – Pipeline by Alion Pharmaceuticals Inc, H2 2019

Parkinson’s Disease – Pipeline by Alkahest Inc, H2 2019

Parkinson’s Disease – Pipeline by Alkermes Plc, H2 2019

Parkinson’s Disease – Pipeline by Allife Medical Science and Technology Co Ltd, H2 2019

Parkinson’s Disease – Pipeline by Alterity Therapeutics Ltd, H2 2019

Parkinson’s Disease – Pipeline by Amabiotics SAS, H2 2019

Parkinson’s Disease – Pipeline by Amarantus Bioscience Holdings Inc, H2 2019

Parkinson’s Disease – Pipeline by Amathus Therapeutics Inc, H2 2019

Parkinson’s Disease – Pipeline by Amneal Pharmaceuticals Inc, H2 2019

Parkinson’s Disease – Pipeline by Anavex Life Sciences Corp, H2 2019

Parkinson’s Disease – Pipeline by Anida Pharma Inc, H2 2019

Parkinson’s Disease – Pipeline by Annovis Bio Inc, H2 2019

Parkinson’s Disease – Pipeline by Antoxis Ltd, H2 2019

Parkinson’s Disease – Pipeline by Aoxing Pharmaceutical Company Inc, H2 2019

Parkinson’s Disease – Pipeline by APeT Holding BV, H2 2019

Parkinson’s Disease – Pipeline by Apollo Therapeutics LLC, H2 2019

Parkinson’s Disease – Pipeline by Appello Pharmaceuticals Inc, H2 2019

Parkinson’s Disease – Pipeline by AptaBio Therapeutics Inc, H2 2019

Parkinson’s Disease – Pipeline by Aptamer Sciences Inc, H2 2019

Parkinson’s Disease – Pipeline by Araclon Biotech SL, H2 2019

Parkinson’s Disease – Pipeline by Aranda Pharma Ltd, H2 2019

Parkinson’s Disease – Pipeline by AriBio, H2 2019

Parkinson’s Disease – Pipeline by ArmaGen Inc, H2 2019”

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports